184 related articles for article (PubMed ID: 33941761)
1. Association of co-occurring opioid or other substance use disorders with increased healthcare utilization in patients with depression.
Vekaria V; Bose B; Murphy SM; Avery J; Alexopoulos G; Pathak J
Transl Psychiatry; 2021 May; 11(1):265. PubMed ID: 33941761
[TBL] [Abstract][Full Text] [Related]
2. Association of opioid or other substance use disorders with health care use among patients with suicidal symptoms.
Vekaria V; Patra BG; Xi W; Murphy SM; Avery J; Olfson M; Pathak J
J Subst Use Addict Treat; 2024 Jan; 156():209177. PubMed ID: 37820869
[TBL] [Abstract][Full Text] [Related]
3. Association of polysubstance use disorder with treatment quality among Medicaid beneficiaries with opioid use disorder.
Smart R; Kim JY; Kennedy S; Tang L; Allen L; Crane D; Mack A; Mohamoud S; Pauly N; Perez R; Donohue J
J Subst Abuse Treat; 2023 Jan; 144():108921. PubMed ID: 36327615
[TBL] [Abstract][Full Text] [Related]
4. Differences among major depressive disorder with and without co-occurring substance use disorders and substance-induced depressive disorder: results from the National Epidemiologic Survey on Alcohol and Related Conditions.
Blanco C; Alegría AA; Liu SM; Secades-Villa R; Sugaya L; Davies C; Nunes EV
J Clin Psychiatry; 2012 Jun; 73(6):865-73. PubMed ID: 22480900
[TBL] [Abstract][Full Text] [Related]
5. High prevalence of co-occurring substance use in individuals with opioid use disorder.
Mahoney JJ; Winstanley EL; Lander LR; Berry JH; Marshalek PJ; Haut MW; Marton JL; Kimble WD; Armistead M; Wen S; Cai Y; Hodder SL
Addict Behav; 2021 Mar; 114():106752. PubMed ID: 33348147
[TBL] [Abstract][Full Text] [Related]
6. Utilization of treatment by Medicaid enrollees with opioid use disorder and co-occurring substance use disorders.
O'Brien P; Henke RM; Schaefer MB; Lin J; Creedon TB
Drug Alcohol Depend; 2020 Dec; 217():108261. PubMed ID: 32979735
[TBL] [Abstract][Full Text] [Related]
7. Polysubstance use and association with opioid use disorder treatment in the US Veterans Health Administration.
Lin LA; Bohnert ASB; Blow FC; Gordon AJ; Ignacio RV; Kim HM; Ilgen MA
Addiction; 2021 Jan; 116(1):96-104. PubMed ID: 32428386
[TBL] [Abstract][Full Text] [Related]
8. Adverse Consequences of Co-Occurring Opioid Use Disorder and Cannabis Use Disorder Compared to Opioid Use Disorder Only.
De Aquino JP; Sofuoglu M; Stefanovics E; Rosenheck R
Am J Drug Alcohol Abuse; 2019; 45(5):527-537. PubMed ID: 31112429
[No Abstract] [Full Text] [Related]
9. Behavioral health treatment utilization among individuals with co-occurring opioid use disorder and mental illness: Evidence from a national survey.
Novak P; Feder KA; Ali MM; Chen J
J Subst Abuse Treat; 2019 Mar; 98():47-52. PubMed ID: 30665603
[TBL] [Abstract][Full Text] [Related]
10. Impact of comorbid opioid use disorder and major depressive disorder on healthcare utilization outcomes in patients with peripheral artery disease: A National Readmission Database analysis.
Amenyedor K; Lee M; Algara M; Siddiqui WT; Hardt M; Romain G; Mena-Hurtado C; Smolderen KG
Vasc Med; 2024 Apr; 29(2):163-171. PubMed ID: 38391134
[TBL] [Abstract][Full Text] [Related]
11. Co-occurring substance use disorders among patients with opioid use disorder in rural primary care clinics.
Zhu Y; Baldwin LM; Mooney LJ; Saxon AJ; Kan E; Hser YI
J Subst Use Addict Treat; 2024 Mar; 158():209269. PubMed ID: 38097045
[TBL] [Abstract][Full Text] [Related]
12. Co-occurring substance use and mental disorders among adults with opioid use disorder.
Jones CM; McCance-Katz EF
Drug Alcohol Depend; 2019 Apr; 197():78-82. PubMed ID: 30784952
[TBL] [Abstract][Full Text] [Related]
13. Polypharmacy Among Patients With Major Depressive Disorder and Co-occurring Substance Use Disorders in a Psychiatric Hospital Setting: Prevalence and Risk Factors.
Benz MB; Epstein-Lubow G; Weinstock LM; Gaudiano BA
J Clin Psychopharmacol; 2023 May-Jun 01; 43(3):273-277. PubMed ID: 37039705
[TBL] [Abstract][Full Text] [Related]
14. Impact of an intervention to implement provision of opioid use disorder medication among patients with and without co-occurring substance use disorders.
Frost MC; Malte CA; Hawkins EJ; Glass JE; Hallgren KA; Williams EC
J Subst Use Addict Treat; 2023 Dec; 155():209175. PubMed ID: 37751798
[TBL] [Abstract][Full Text] [Related]
15. Mental health and substance use disorder comorbidities among Medicaid beneficiaries: Associations with opioid use disorder and prescription opioid misuse.
Swartz JA; Franceschini D; Scamperle K
AIMS Public Health; 2023; 10(3):658-677. PubMed ID: 37842281
[TBL] [Abstract][Full Text] [Related]
16. Treatment-resistant depression as risk factor for substance use disorders-a nation-wide register-based cohort study.
Brenner P; Brandt L; Li G; DiBernardo A; Bodén R; Reutfors J
Addiction; 2019 Jul; 114(7):1274-1282. PubMed ID: 30938020
[TBL] [Abstract][Full Text] [Related]
17. Adverse events among adult Medicaid enrollees with opioid use disorder and co-occurring substance use disorders.
O'Brien P; Henke RM; Schaefer MB; Lin J; Creedon TB
Drug Alcohol Depend; 2021 Apr; 221():108555. PubMed ID: 33596496
[TBL] [Abstract][Full Text] [Related]
18. Treatment utilization among persons with opioid use disorder in the United States.
Wu LT; Zhu H; Swartz MS
Drug Alcohol Depend; 2016 Dec; 169():117-127. PubMed ID: 27810654
[TBL] [Abstract][Full Text] [Related]
19. Chronic non-cancer pain among adults with substance use disorders: Prevalence, characteristics, and association with opioid overdose and healthcare utilization.
John WS; Wu LT
Drug Alcohol Depend; 2020 Apr; 209():107902. PubMed ID: 32088587
[TBL] [Abstract][Full Text] [Related]
20. The Canadian Network for Mood and Anxiety Treatments (CANMAT) task force recommendations for the management of patients with mood disorders and comorbid substance use disorders.
Beaulieu S; Saury S; Sareen J; Tremblay J; Schütz CG; McIntyre RS; Schaffer A;
Ann Clin Psychiatry; 2012 Feb; 24(1):38-55. PubMed ID: 22303521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
